Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Clinical & Experimental Metastasis|July 7, 2014
Annexin A1 in primary tumors promotes melanoma disseminationZied Boudhraa, Fabien Rondepierre, Lemlih Ouchchane, et al.Archives of Dermatology|June 22, 2005
Prediction of survival for patients with bullous pemphigoid: a prospective studyPascal Joly, Jacques Benichou, Catherine Lok, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2013
(123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trialFlorent Cachin, Elisabeth Miot-Noirault, Brigitte Gillet, et al.The Journal of Investigative Dermatology|December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General PopulationMarthe Plaquevent, Florence Tétart, Laurence Fardet, et al.The British Journal of Dermatology|March 10, 2026
Combined methotrexate and short-term superpotent topical corticosteroids compared with prolonged superpotent topical corticosteroids alone in bullous pemphigoid: a multicentre, noninferiority randomised clinical trialOlivier Dereure, Philippe Bernard, Olivier Chosidow, et al.Nature Medicine|September 5, 2017
Mutations in ACTRT1 and its enhancer RNA elements lead to aberrant activation of Hedgehog signaling in inherited and sporadic basal cell carcinomasElodie Bal, Hyun-Sook Park, Zakia Belaid-Choucair, et al.JAMA Dermatology|January 24, 2024
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 TrialBillal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, et al.Lancet (London, England)|March 27, 2017
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialPascal Joly, Maud Maho-Vaillant, Catherine Prost-Squarcioni, et al.JAMA Dermatology|March 19, 2020
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical TrialClaire Mignard, Maud Maho-Vaillant, Marie-Laure Golinski, et al.The Journal of Investigative Dermatology|October 11, 2018
Large International Validation of ABSIS and PDAI Pemphigus Severity ScoresVivien Hébert, Claire Boulard, Estelle Houivet, et al.Pageof 4